• If you are wondering whether Johnson & Johnson stock still offers value after a strong run, the key is to look closely at what the current price implies versus what you are getting as a shareholder.
• The stock last closed at US$228.17, with returns of 10.0% year to date and 52.2% over the past year. The share price has slipped about 1.1% over the past week and gained 1.2% over the last 30 days, hinting that views on risk and reward are still shifting.
• Recent headlines around Johnson & Johnson have focused on ongoing product and legal developments, as well as its position in large scale healthcare markets. These factors continue to shape how investors think about its long term prospects and help explain why the stock’s longer term performance differs from the shorter term moves.
• Simply Wall St currently gives Johnson & Johnson a valuation score of 4 out of 6. The rest of this article will unpack what that means by comparing different valuation approaches, then conclude with a broader way to think about whether the current price truly reflects the full story.

Approach 1: Johnson & Johnson Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes expected future cash flows, then discounts them back to today using a required rate of return. The aim is to estimate what those future cash flows are worth in today’s dollars.

For Johnson & Johnson, the model used is a 2 stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $17.0b. Analyst inputs and extrapolated estimates point to projected free cash flow of $35.9b by 2030, with a series of annual projections in between that are all converted into today’s value using the chosen discount rate.

Adding up those discounted cash flows gives an estimated intrinsic value of $374.05 per share. Versus the recent share price of $228.17, this implies the stock is trading at a 39.0% discount to the DCF estimate, which points to a meaningful gap between price and this particular cash flow based valuation.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Johnson & Johnson is undervalued by 39.0%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Approach 2: Johnson & Johnson Price vs Earnings

For profitable companies, the P/E ratio is a useful way to see how much you are paying for each dollar of current earnings. It ties the share price directly to the business’s ability to generate profit, which is usually more stable than revenue alone.

What counts as a “normal” P/E depends on what investors expect for future growth and how risky those earnings appear. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually points to a lower multiple.

Johnson & Johnson currently trades on a P/E of 26.11x. That is below the average of its directly compared peers at 27.10x, and above the wider Pharmaceuticals industry average of 15.29x. Simply Wall St’s Fair Ratio for Johnson & Johnson is 26.30x, which is a proprietary estimate of what the P/E might be given its earnings profile, industry, profit margins, market value and risk factors.

The Fair Ratio can be more informative than a simple peer or industry comparison because it adjusts for company specific traits rather than assuming one size fits all. With the current 26.11x P/E sitting very close to the 26.30x Fair Ratio, the market price looks broadly aligned with this multiple based view.

Result: ABOUT RIGHT

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 21 top founder-led companies.

Upgrade Your Decision Making: Choose your Johnson & Johnson Narrative

Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story to your numbers by linking your view of Johnson & Johnson’s business to a forecast for revenue, earnings and margins, and then to a Fair Value that you can compare to today’s price to help inform a decision on whether to buy, hold or sell. This all happens within an accessible tool on the Community page that updates when new information such as news or earnings is added. One investor might build a Narrative around Johnson & Johnson as a defensive compounder with a Fair Value of US$148.64, while another focuses on an AI powered pipeline or a more optimistic long term outlook with Fair Values around US$230.82 or US$265.00. A more cautious investor may anchor to a lower Fair Value such as US$181.77 or even US$146.57, each reflecting a different but transparent story behind the stock.

For Johnson & Johnson however we'll make it really easy for you with previews of two leading Johnson & Johnson Narratives:

Fair Value: US$265.00

Implied undervaluation vs last close: 14.0%

Revenue growth assumption: 7.10%

• Centres on a broad set of US$1b plus pharmaceutical and MedTech platforms, with oncology, immunology, neuroscience and cardiovascular therapies feeding a large pipeline of potential future products.
• Builds in analyst expectations for revenue growth, a future profit margin of about 22.6% and earnings of US$26.2b by 2029, alongside a higher P/E multiple relative to today and to the wider US Pharmaceuticals industry.
• Highlights concentration in blockbuster assets, pricing and policy pressure, higher fixed costs, acquisition execution risk and legal exposure as key factors that could challenge the bullish case.

Fair Value: US$148.64

Implied overvaluation vs last close: 53.6%

Revenue growth assumption: 4.73%

• Frames Johnson & Johnson as a mature healthcare company with diversified revenue by geography and segment, and uses that profile to anchor more moderate growth and returns.
• Blends a 10 year DCF, a 10 year Dividend Discount Model and a historical dividend yield cross check to arrive at an overall fair value of US$148.64 per share.
• Argues that, at this level, the stock price sits above those blended value estimates, while still reflecting a company with long running dividends and what the author sees as durable earnings power.

Do you think there's more to the story for Johnson & Johnson? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.